论文部分内容阅读
１９８０～１９９３年，用（１３１）Ⅰ－抗ＡＦＰ抗体治疗不能切除肝癌７２例（１５３例次），治疗≥２次占４７例，平均（１３１）Ⅰ量为３１．８７（６．４～９７．４）Ｍｃｉ，中位数２７．４ｍｃｉ（１０１３．８ＭＢｑ）。结果：总有效率２０．８％（１５／７２），治后一年生存率３３．３％（２２／６６）；治疗≥２，≥３，≥４次者有效率分别为２９．８％（１４／４７）、６０．０％（９／１５）和７０．０％（７／１０）；一年生存率依次为４５．７％、７３．３％和８０．０％；瘤大小：≤７ｃｍ，７．１～１０ｃｍ和＞１０ｃｍ患者，治后瘤缩小率分别为１００．０％、７６．９％和５３．９％；一年生存率８７．５％、４８．０％和１５．４％；经肝动脉灌注治疗有效率高于ｉｖ给药者（６４．３％：１５．２％），一年生存率亦高于ｉｖ（６４．３％：３７．５％）。本研究表明，（１３１）Ⅰ－抗ＡＦＰ抗体导向治疗肝癌具有明显疗效。
From 1980 to 1993, 72 cases (153 cases) could not be excised with (131)I-anti-AFP antibody treatment, and 47 cases were treated ≥2 times with an average (131) I level of 31.87 (6.4-97). .4) Mci, median 27.4mci (1013.8MBq). Results: The total effective rate was 20.8% (15/72). The one-year survival rate after treatment was 33.3% (22/66). The treatment efficiency was ≥ 2, ≥ 3, and ≥ 4 times. The effective rate was 29.8%. (14/47), 60.0% (9/15), and 70.0% (7/10); one-year survival rates were 45.7%, 73.3%, and 80.0%, respectively; tumor size: In patients with ≤7cm, 7.1～10cm and >10cm, the tumor reduction rate after treatment was 100.0%, 76.9% and 53.9%, respectively; the one-year survival rate was 87.5%, 48.0% and 15 The rate of hepatic arterial infusion was higher than that of iv administration (64.3%:15.2%), and the 1-year survival rate was also higher than that of iv (64.3%: 37.5%). This study shows that (131) I-anti-AFP antibody-oriented treatment of liver cancer has a significant effect.